Originalis B.V. secures contract for Pharmaceutical products - Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Emtricitabine Rilpivirine Tenofovir disoproxil fumarate, ATC J05AR08 f d Z 010924 - 310826

Netherlands, Sept. 4 -- Netherlands based Originalis B.V. has secured contract from DAK-Gesundheit for Pharmaceutical products - Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Emtricitabine Rilpivirine Tenofovir disoproxil fumarate, ATC J05AR08 f d Z 010924 - 310826 . The value of the contract is not disclosed .

Published by HT Digital Content Services with permission from Pivotal Sources....